Assessment of non-derivatized beta-N-methylamino-L-alanine (BMAA) neurotoxin in free form in urine of patients with nonspecific neurological symptoms

Investor logo

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Faculty of Science. Official publication website can be found on muni.cz.
Authors

BLÁHOVÁ Lucie KOHOUTEK Jiří KADLECOVA E. KOZAKOVA L. BLÁHA Luděk

Year of publication 2017
Type Article in Periodical
Magazine / Source Toxicon
MU Faculty or unit

Faculty of Science

Citation
Web https://www.sciencedirect.com/science/article/pii/S0041010117301277?via%3Dihub
Doi http://dx.doi.org/10.1016/j.toxicon.2017.04.011
Keywords Liquid chromatography-tandem mass spectrometry (LC-MS/MS); Hydrophilic interaction liquid chromatography (HILIC); Beta-N-methylamino-L-alanine (BMAA); Human urine
Description The beta-N-methylamino-L-alanine (BMAA) is a non-proteinogenic amino acid discussed to be produced by cyanobacteria forming harmful blooms. Since BMAA is suspected etiological agent in neurodegenerative diseases, there is a need to study and validate whether and in what concentrations can BMAA be present in human tissues. The aim of the present study was to validate analytical and extraction procedures for quantification of non-derivatized BMAA in the urine using liquid chromatography and commercial ELISA Kit. The study was focused on BMAA in different forms - dissolved, protein associated and total. The validated protocol included SPE followed by HILIC MS/MS for analyses of non-derivatized free form of BMAA with a limit of quantification 20 ng/mL. The methods for other BMAA forms (i.e.protein-associated and total) were also assessed but high matrix interferences did not allow their implementation. The method was used for analyses of free BMAA in 23 urine samples from healthy volunteers and psychiatric patients suffering from nonspecific neurological symptoms. Traces of BMAA were suspectedly detected in a single urine sample but they were not unequivocally proved according to all conservative analytical criteria. BMAA was also not confirmed in a repeatedly collected sample from the same person. The evaluated commercial BMAA ELISA Kit (Abraxis) was not suitable for determination of BMAA in extracted urine samples because of systematically highly false positive results. In agreement with recent findings, analyses of BMAA appear to methodologically challenging, and further research on BMAA in human tissues (or its precursors with potency to form BMAA under natural conditions or eventually - during sample processing) is needed to clarify its potential ethiological role in neurodegenerative diseases.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.